| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Osteoporosis is associated with a decrease in bone mass, which is maintained by bone-forming osteoblasts and bone-resorbing osteoclasts. We demonstrated that ephrinB2 increased osteoblastic differentiation and decreased osteoclastic differentiation in vitro, and that intravenously injected ephrinB2 ameliorated the bone loss observed in osteoporotic mice. Moreover, we constructed bone-targeting ephrinB2, named as AcOP-ephrinB2, to maximize the therapeutic effect against osteoporosis. However, high dose of AcOP-ephrinB2 showed little anti-osteoporotic effect in osteoporotic mice, that is, long-term and large-amount of accumulation of AcOP-ephrinB2 in bone appeared to be disadvantage in the treatment for osteoporosis.
|
